bioMérieux S.A. (BMXMF)
bioMérieux S.A. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Marcy l'Étoile, ARA, FR. The stock last traded at $83.27, up 0.00% on the session, giving a market capitalisation of $9.82B. On trailing twelve-month figures it carries a trailing P/E of 19.77, a net margin of 11.6%. Its beta of 0.57 implies it has historically moved less than the broad market.
Operating on a global scale, bioMérieux S.A. designs and produces in vitro diagnostic solutions specifically for detecting infectious diseases across the Americas, Europe, the Middle East, Africa, and Asia Pacific. The firm's offerings encompass diagnostic systems that analyze biological samples to identify infectious diseases, cardiovascular conditions, and various types of cancer. Furthermore, it provides essential microbiological testing for quality assurance within the food, pharmaceutical, cosmetics, and veterinary industries. Its diverse clientele includes clinical and hospital laboratories, medical professionals, blood banks, and industrial control facilities. Founded in 1963, initially under the name B-D Mérieux, bioMérieux S.A. is headquartered in Marcy l'Etoile, France, and functions as a subsidiary of Institut Mérieux SA.
bioMérieux S.A. is most often compared with the following Healthcare names: